Gossamer Bio Financial Statements (GOSS)
|
|
|
|
Report date
|
|
|
03.03.2022 |
17.03.2023 |
05.03.2024 |
13.03.2025 |
17.03.2026 |
|
15.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
114.7 |
48.5 |
|
55.5 |
|
Operating Income, bln rub |
|
|
-216.1 |
-218.6 |
-183.8 |
-59.9 |
-163.3 |
|
-178.8 |
|
EBITDA, bln rub |
? |
|
-209.4 |
-211.1 |
-161.9 |
-40.0 |
-162.3 |
|
-170.0 |
|
Net profit, bln rub |
? |
|
-234.0 |
-229.4 |
-179.8 |
-56.5 |
-170.4 |
|
-180.4 |
|
|
OCF, bln rub |
? |
|
-188.9 |
-187.0 |
-159.2 |
-3.47 |
-171.3 |
|
-170.3 |
|
CAPEX, bln rub |
? |
|
1.62 |
0.475 |
0.000 |
0.000 |
0.079 |
|
0.053 |
|
FCF, bln rub |
? |
|
-190.5 |
-187.5 |
-159.2 |
-3.47 |
-171.3 |
|
-170.3 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
216.1 |
218.6 |
183.8 |
174.6 |
210.7 |
|
234.3 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
1.00 |
|
0.232 |
|
R&D, bln rub |
|
|
170.3 |
170.9 |
135.3 |
138.5 |
174.1 |
|
186.6 |
|
Interest expenses, bln rub |
|
|
19.4 |
13.9 |
13.5 |
11.5 |
11.0 |
|
11.0 |
|
|
Assets, bln rub |
|
|
343.7 |
272.5 |
311.9 |
315.3 |
172.2 |
|
128.9 |
|
Net Assets, bln rub |
? |
|
121.5 |
12.1 |
62.8 |
29.5 |
-122.8 |
|
-161.5 |
|
Debt, bln rub |
|
|
185.2 |
225.7 |
212.5 |
202.9 |
202.0 |
|
202.9 |
|
Cash, bln rub |
|
|
325.2 |
255.7 |
296.4 |
294.5 |
136.9 |
|
99.2 |
|
Net debt, bln rub |
|
|
-140.0 |
-29.9 |
-84.0 |
-91.6 |
65.0 |
|
103.7 |
|
|
Ordinary share price, rub |
|
|
11.3 |
2.17 |
0.913 |
0.905 |
3.10 |
|
0.340 |
|
Number of ordinary shares, mln |
|
|
74.8 |
84.6 |
225.6 |
226.2 |
228.5 |
|
234.1 |
|
|
Market cap, bln rub |
|
|
846 |
184 |
206 |
205 |
708 |
|
80 |
|
EV, bln rub |
? |
|
706 |
154 |
122 |
113 |
773 |
|
183 |
|
Book value, bln rub |
|
|
121 |
12 |
63 |
29 |
-123 |
|
-161 |
|
|
EPS, rub |
? |
|
-3.13 |
-2.71 |
-0.80 |
-0.25 |
-0.75 |
|
-0.77 |
|
FCF/share, rub |
|
|
-2.55 |
-2.22 |
-0.71 |
-0.02 |
-0.75 |
|
-0.73 |
|
BV/share, rub |
|
|
1.62 |
0.14 |
0.28 |
0.13 |
-0.54 |
|
-0.69 |
|
|
EBITDA margin, % |
? |
|
|
|
|
-34.8% |
-334.7% |
|
-306.1% |
|
Net margin, % |
? |
|
|
|
|
-49.3% |
-351.5% |
|
-324.8% |
|
FCF yield, % |
? |
|
-22.5% |
-102.2% |
-77.3% |
-1.69% |
-24.2% |
|
-213.9% |
|
ROE, % |
? |
|
-192.7% |
-1 899% |
-286.5% |
-191.7% |
138.8% |
|
111.7% |
|
ROA, % |
? |
|
-68.1% |
-84.2% |
-57.6% |
-17.9% |
-98.9% |
|
-140.0% |
|
|
P/E |
? |
|
-3.62 |
-0.80 |
-1.14 |
-3.62 |
-4.16 |
|
-0.44 |
|
P/FCF |
|
|
-4.44 |
-0.98 |
-1.29 |
-59.0 |
-4.13 |
|
-0.47 |
|
P/S |
? |
|
|
|
|
1.78 |
14.6 |
|
1.43 |
|
P/BV |
? |
|
6.97 |
15.2 |
3.28 |
6.94 |
-5.77 |
|
-0.49 |
|
EV/EBITDA |
? |
|
-3.37 |
-0.73 |
-0.75 |
-2.83 |
-4.77 |
|
-1.08 |
|
Debt/EBITDA |
|
|
0.67 |
0.14 |
0.52 |
2.29 |
-0.40 |
|
-0.61 |
|
|
R&D/CAPEX, % |
|
|
10 504% |
35 983% |
|
|
220 371% |
|
352 081% |
|
|
CAPEX/Revenue, % |
|
|
|
|
|
0.00% |
0.16% |
|
0.10% |
|
| Gossamer Bio shareholders |
